Intech Biopharm Corporation (TPEX:6461)

Market Cap	2.74B +6.3%
Revenue (ttm)	54.34M -52.3%
Net Income	-474.56M
EPS	-4.42
Shares Out	110.32M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	97,796
Open	25.15
Previous Close	25.00
Day's Range	24.35 - 25.45
52-Week Range	22.79 - 42.44
Beta	0.08
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 18, 2026

About Intech Biopharm

Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. The company offers combinations, formulations, and generic drugs for the treatment of respiratory diseases using technology platforms, such as inhaled low ethanol formulation, a metered dose inhaler platform for treating asthma and COPD, as well as dry powder inhaler that comprises blisters and capsules. Its products include SYN006, SYN010, SYN007, Synflutide, Duasma,Synvent, and SYN011. The company was ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 96
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6461

Financial Performance

In 2025, Intech Biopharm's revenue was 107.53 million, an increase of 170.31% compared to the previous year's 39.78 million. Losses were -389.03 million, 5.66% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 13, 2026

Data Sources Report a data error